Yamamoto Chika, Yoshikawa Hiromasa, Fukumoto Shunsuke, Higuchi Takashi, Yoshida Masanori, Horinouchi Yasufumi, Uehara Satoru, Yasumori Koutarou
Dept. of Dentistry, Oral and Maxillofacial Surgery, Clinical Research Institute, National Hospital Organization Kyushu Medical Center.
Gan To Kagaku Ryoho. 2011 Dec;38(13):2575-8.
Combination therapy with S-1, superselective intra-arterial infusion of CBDCA and radiation therapy has been used to treat patients with oral cancer since 2005. In this study, the histopathological effects and toxicities following concurrent chemoradiotherapy were examined. The subjects consisted of 15 patients (10 men and 5 women) who were treated with S-1 (60-80 mg/day, 4 weeks), superselective intra-arterial infusion of CBDCA (300 mg/body) and radiation therapy (total dose 30-36 Gy) in our department from 2005 to 2009. Nine patients, showed T2 disease, 3 showed T3 disease, and another 3 showed T4 diseases. The primary cancer sites were the tongue (6 cases), buccal mucosa (4 cases), mandible gingival (3 cases), maxillary gingiva (1 case), and the floor of the mouth (1 case). The histopathological effects were evaluated according to Oboshi-Shimosato classification. Grade IV was shown in 10 cases (66. 7%), grade III in 1 case (6. 7%), II bin 3 cases (20. 0%), and II a in 1 case (6. 7%). All patients completed the treatment. The pathological response of the resected tumor was grade IIbor higher in 14 cases (93. 3%). While good histological effects were noted, there was one patient for whom viable tumor cells remained in the central part of the tumor. The present study indicates that further investigation is needed to determine the best dosing and dosing schedule.
自2005年以来,S-1、超选择性动脉内输注卡铂和放射治疗的联合疗法已被用于治疗口腔癌患者。在本研究中,对同步放化疗后的组织病理学效应和毒性进行了检查。研究对象包括15例患者(10例男性和5例女性),他们于2005年至2009年在我院接受了S-1治疗(60-80mg/天,共4周)、超选择性动脉内输注卡铂(300mg/人)和放射治疗(总剂量30-36Gy)。9例患者为T2期疾病,3例为T3期疾病,另外3例为T4期疾病。原发癌部位为舌(6例)、颊黏膜(4例)、下颌牙龈(3例)、上颌牙龈(1例)和口底(1例)。根据大星-下里分类法评估组织病理学效应。10例(66.7%)显示为IV级,1例(6.7%)为III级,3例(20.0%)为IIb级,1例(6.7%)为IIa级。所有患者均完成了治疗。切除肿瘤的病理反应在14例(93.3%)中为IIb级或更高。虽然观察到良好的组织学效应,但有1例患者肿瘤中央仍存在存活的肿瘤细胞。本研究表明,需要进一步研究以确定最佳剂量和给药方案。